Centre Hospitalier De Carcassonne

At Centre Hospitalier De Carcassonne, the Oncology research program focuses strongly on neoplasms, with studies exploring how to improve treatment results for several cancer types. The work includes testing new or adjusted therapies, refining adjuvant care, and using molecular or biomarker information to guide more personalized treatment choices.

• Endometrial cancer research in p53abn HREC is examining whether maintenance olaparib can help reduce recurrence after chemoradiotherapy.
• Colorectal cancer studies are using ctDNA to better identify patients who may benefit from additional treatment after surgery and chemotherapy.
• Trials in gastric cancer and gastroesophageal junction adenocarcinoma are evaluating combinations designed to improve treatment effectiveness in the first-line setting.
• Research in breast cancer is assessing whether some patients with HR+ HER2- disease can safely receive less intensive adjuvant treatment while maintaining good outcomes.

This area reflects a clear interest in tailoring cancer care across digestive system diseases, hemic and lymphatic diseases, and respiratory tract diseases, with a mix of treatment optimization and response-guided strategies.

A major part of the site's clinical trial activity centers on digestive system diseases, especially colon carcinoma, rectal adenocarcinoma, and gastric cancer. These studies aim to improve survival, preserve organ function when possible, and refine the use of chemotherapy in patients with different risk profiles.

• Studies in colon carcinoma are testing ctDNA-guided approaches to decide who needs adjuvant treatment.
• Research in older adults with rectal cancer is comparing strategies intended to improve organ preservation.
• Trials in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma are evaluating combination regimens to strengthen treatment response.
• Some studies focus on whether adapted chemotherapy can provide benefit while limiting toxicity in patients with colorectal cancer.

This research supports more individualized care for gastrointestinal cancers, with attention to both effectiveness and quality of life.

The site also contributes to research in respiratory tract diseases, mainly non-small cell lung cancer and locally advanced squamous cell carcinoma. These trials are designed to evaluate whether new immunotherapy or chemotherapy combinations can improve outcomes in patients who need better first-line or maintenance treatment options.

• Non-small cell lung cancer studies are examining maintenance treatment approaches to extend disease control.
• Trials in older patients with advanced lung cancer are testing immunotherapy added to standard treatment to improve survival.
• Research in squamous cell carcinoma is evaluating adapted chemotherapy to balance response and tolerability.

These studies highlight ongoing efforts to improve treatment effectiveness in lung cancer while keeping side effects manageable.

Beyond cancer, the research portfolio includes cardiovascular diseases, particularly prevention strategies for type 2 diabetes patients who have not yet had a cardiovascular event. The goal is to determine whether commonly used anti-inflammatory or antiplatelet approaches can lower future heart and stroke risk.

• Studies are evaluating whether colchicine can reduce major cardiovascular events in high-risk adults with diabetes.
• Research is also assessing whether low-dose aspirin may help prevent serious cardiovascular complications.
• The focus is on improving long-term protection for patients at elevated risk but without known cardiovascular disease.

This work broadens the site's clinical research profile by addressing prevention and risk reduction in chronic disease care.

Several trials at the site sit at the intersection of hemic and lymphatic diseases, biomarker-driven oncology, and treatment tailoring. These studies are designed to identify which patients are most likely to benefit from a given approach and to reduce unnecessary treatment burden when possible.

• Research using circulating tumor DNA is helping guide treatment decisions after surgery in colorectal cancer.
• Studies in early breast cancer are testing whether adjuvant care can be simplified without reducing effectiveness.
• Molecularly informed work in endometrial cancer is exploring targeted maintenance treatment after standard therapy.

This theme reflects a strong interest in precision medicine, with trials focused on matching treatment intensity to individual risk.